N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists
申请人:E.R. SQUIBB & SONS, INC.
公开号:EP0558258A1
公开(公告)日:1993-09-01
Compounds of the formula
inhibit endothelin, wherein:
one of X and Y is N and the other is O; R is naphthyl or naphthyl substituted with R¹, R² and R³;
R¹, R² and R³ are each independently hydrogen; alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, or aralkyl, any of which may be substituted with Z¹, Z² and Z³; halo; hydroxyl; cyano; nitro; -C(O)H; -C(O)R⁶; CO₂H; -CO₂R⁶; -SH; -S(O)nR⁶; -S(O)m-OH; -S(O)m-OR⁶; -O-S(O)m-R⁶; -O-S(O)mOH; -O-S(O)m-OR⁶; -Z⁴-NR⁷R⁸; or -Z⁴-N(R¹¹)-Z⁵⁻NR⁹R¹⁰;
R⁴ and R⁵ are each independently hydrogen; alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, or aralkyl, any of which may be substituted with Z¹, Z² and Z³; halo; hydroxyl; cyano; nitro; -C(O)H; -C(O)R⁶; -CO₂H; -CO₂R⁶; -SH, -S(O)nR⁶; -S(O)m-OH; -S(O)m-OR⁶; -O-S(O)m-R⁶; -O-S(O)mOH; -O-S(O)m-OR⁶; -Z⁴-NR⁷R⁸; -Z⁴-N(R¹¹)-Z⁵⁻ NR⁹R¹⁰; or R⁴ and R⁵ together are alkylene or alkenylene (either of which may be substituted with Z¹, Z² and Z³), completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached.
式中的化合物
抑制内皮素,其中
X 和 Y 中的一个是 N,另一个是 O;R 是萘基或被 R¹、R² 和 R³ 取代的萘基;
R¹、R² 和 R³ 各自独立地为氢;烷基、烯基、炔基、烷氧基、环烷基、环烷基烷基、环烯基、环炔基烷基、芳基或芳烷基,其中任何一个可被 Z¹、Z² 和 Z³ 取代;卤素;羟基;氰基;硝基;-C(O)H;-C(O)R⁶;CO₂H;-CO₂R⁶;-SH;-S(O)nR⁶;-S(O)m-OH;-S(O)m-OR⁶;-O-S(O)m-R⁶;-O-S(O)mOH;-O-S(O)m-OR⁶;-⁴-NR⁷R⁸;或-Z⁴-N(R¹)-Z⁵-NR⁹R¹⁰;
R⁴ 和 R⁵ 各自独立地为氢;烷基、烯基、炔基、烷氧基、环烷基、环烷基烷基、环烯基、环炔基烷基、芳基或芳烷基,其中任何一个可被 Z¹、Z² 和 Z³ 取代;卤素;羟基;氰基;硝基;-C(O)H;-C(O)R⁶;-CO₂H;-CO₂R⁶;-SH,-S(O)nR⁶;-S(O)m-OH;-S(O)m-OR⁶;-O-S(O)m-R⁶;-O-S(O)mOH;-O-S(O)m-OR⁶;-Z⁴-NR⁷R⁸;-Z⁴-N(R¹¹)-Z⁵- NR⁹R¹⁰;或 R⁴ 和 R⁵ 合在一起是亚烷基或烯基(其中任一可被 Z¹、Z² 和 Z³ 取代),与它们所连接的碳原子一起完成一个 4 至 8 元饱和、不饱和或芳香环。